Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 619 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR A Remarkable Group of Patients with Haematological Disorders with No or... December 15, 2021 Coming together for Zynlonta July 2, 2021 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... April 21, 2022 Load more HOT NEWS Worse Survival Observed Among Patients Diagnosed with Cancer During the First... Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... Workout Wednesdays – Chest Exercises Part 2 VA Study Finds No Disparities in Prostate Cancer Deaths with Equal...
